Effectiveness and Safety of Yiqitongluo Granule for Stroke

• Status: Completed
• Trial end date: 2017-12-06
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the prospective study is to evaluate the effectiveness and safety of Yiqitongluo granule in the treatment of stroke with qi-deficiency and blood-stasis in more than sixy hospitals all over China.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yi Yang
• Collaborator: Shineway Pharmaceutical Co.,Ltd

Criteria

Inclusion Criteria:

• mild and moderate ischemic stroke patient with 4-25 NIHSS score

• stable patients within 1 week to 3 months

• sign informed consent before study

Exclusion Criteria:

• CT shows cerebral hemorrhage disease: such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, and subarachnoid hemorrhage

• severe disturbance of consciousness

• dysphagia

• TIA

• hemorrhagic diathesis

• patient with malignant tumor whose expected lifetime is less than 3 months

• allergic constitution

• gestation period, lactation period, woman with the possibility or plan of pregnancy

• those who participated in other clinical trials within 3 months or taking part in other clinical trials